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Edited by Sandro SonninoAbstract Type II fatty acid synthesis (FAS II) is an essential
process for bacteria survival, and malonyl-CoA:acyl carrier pro-
tein transacylase (MCAT) is a key enzyme in FAS II pathway,
which is responsible for transferring the malonyl group from
malonyl-CoA to the holo-ACP by forming malonyl-ACP. In this
work, we described the cloning, characterization and enzymatic
inhibition of a new MCAT from Helicobacter pylori strain SS1
(HpMCAT), and the gene sequence of HpfabD was deposited in
the GenBank database (Accession No. AY738332). Enzymatic
characterization of HpMCAT showed that the Km value for
malonyl-CoA was 21.01 ± 2.3 lM, and the thermal- and guanid-
inium hydrochloride-induced unfolding processes for HpMCAT
were quantitatively investigated by circular dichroism spectral
analyses. Moreover, a natural product, corytuberine, was discov-
ered to demonstrate inhibitory activity against HpMCAT with
IC50 value at 33.1 ± 3.29 lM. Further enzymatic assay results
indicated that corytuberine inhibits HpMCAT in an uncompeti-
tive manner. To our knowledge, this is the ﬁrstly reported
MCAT inhibitor to date. This current work is hoped to supply
useful information for better understanding the MCAT features
of H. pylori strain, and corytuberine might be used as a potential
lead compound in the discovery of the antibacterial agents using
HpMCAT as target.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Fatty acid biosynthesis is an essential pathway for the sur-
vival of the organism since fatty acid is the major components
of cell membrane and possesses important biological function.
In nature, according to the enzyme involved in the pathway,
fatty acid biosynthesis (FAS) is divided into two types, type
I (FAS I) and type II (FAS II) [1–3]. In FAS I system, found
in animals, the biosynthesis of fatty acid is catalyzed by a
multi-enzyme, which is a single polypeptide with eight distinctAbbreviations: FAS, fatty acid biosynthesis; ACP, acyl carrier protein;
MCAT, malonyl-CoA:acyl carrier protein transacylase; CD, circular
dichroism; GndHCl, guanidinium hydrochloride; KDH, a-ketoglutar-
ate dehydrogenase
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carried out by a series of structurally dissociated enzymes as
discovered in most of the bacteria [1,2]. Due to the large diﬀer-
ences between these two FAS systems, the enzymes involved in
the type II fatty acid biosynthesis have been developed as the
attractive targets for the discovery of antibacterial agents [2].
Malonyl-CoA:acyl carrier protein transacylase (MCAT;
FabD; EC2.3.1.39) is a vital enzyme within FAS II system, it
catalyzes the transfer of a malonyl moiety from malonyl-CoA
to holo-ACP, forming malonyl-ACP as the elongation sub-
strate for the fatty acid biosynthesis [4–7]. The research has
indicated that MCAT is essential for the completion of fatty
acid synthesis, and the genetic inactivation of fabD is lethal
in all pathogens [6,8,9]. Moreover, according to the recent re-
port that the MCAT might participate in polyketide biosynthe-
sis, it was regarded as the possible link between fatty acid and
polyketide biosynthesis [10–12]. Therefore, MCAT has become
a promising target in the discovery of antibacterial agents.
The solved crystal structures of MCAT from Escherichia coli
(EcMCAT) (PDB code:1MLA) and Streptomyces coelicolor
(ScMCAT) (PDB code:1NM2) indicated that both of these
structures have similar structures, and the catalytic active site
is composed of two subdomains [10,13,14]. One is made up
of a short four-stranded parallel b-sheet and 12 helices, and
the other contains a four-stranded anti-parallel b-sheet and
two helices. The active residue (Ser 97) is reported to locate
in the canyon of the two subdomains [10]. The overall struc-
ture of MCAT could be thus generally depicted as a typical
a/b hydrolase model [10,13]. It is known that MCAT performs
the transfer of malonyl group to the holo-ACP via the ping-
pong bi–bi mechanism involving the His-Ser catalytic domain
commonly contained in the serine-dependent acylhydrolases.
The unusual feature for this mechanism is related to the exis-
tence of the stable MCAT-malonyl intermediate, while in most
hydrolases, the formed possible enzyme-substrate intermedi-
ates might be rapidly broken down by the nucleophilic attack
from the water molecules. It is reported that the formed stable
MCAT-malonyl intermediate might be ascribed to the key res-
idues of Arg117, Gln11, Gln63 in the structure of MCAT,
which could interact with the malonate carboxylate group
[2,10,13,15].
In recent years, bacterial diseases and antibiotic-resistant
infections are globally increasing. They have become world-
wide problems and governed the urgent needs for new drug de-
sign based on novel antibacterial targets [1,2,16]. Helicobacter
pylori is a gram-negative clinic pathogenic bacterium, which is
related to peptic ulcer and gastric cancer [17,18]. In this work,blished by Elsevier B.V. All rights reserved.
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strain and some biochemical characterization was also per-
formed against this enzyme. In addition, a natural product,
corytuberine, was discovered to demonstrate inhibitory activ-
ity against HpMCAT in an uncompetitive manner. Corytuber-
ine is a kind of alkaloid with multi-pharmacological activity.
To our knowledge, this is the ﬁrstly reported MCAT inhibitor
to date. Our work is hoped to supply useful information for
better understanding the MCAT features of H. pylori strain,
and the inhibitor corytuberine might be used as a potential
lead compound in the discovery of antibacterial agents.2. Materials and methods
2.1. Materials and strains
H. pylori strain SS1 was obtained from our institute. E. coli host
strain M15 was purchased from Qiagen. The natural product corytub-
erine (Fig. 1) was from a chemical library containing 5000 compounds
established in our lab. All other chemicals were of reagent grade or ul-
tra-pure quality, and commercially available.
2.2. Cloning of the fabD gene from H. pylori (HpfabD)
Based on the genome sequences of H. pylori strains 26695 and
J99 (GenBank Accession Nos. NC_000915 and NC_000921), two
polymerase chain reaction (PCR) primers (forward: 5 0-CAAAATC-
CACGCCAAACAATTCTAG-3 0 and reverse: 5 0-CTTTAATGGTT-
TCTAAACAAAACTAAGGGC-30) were designed to amplify the
corresponding region containing fabD gene from the chromosome
of H. pylori strain SS1. The genomic DNA of H. pylori strain
SS1 as a template was prepared by using Genomic DNA Extraction
Kit (Sangon). The reaction was performed for 30 cycles: 45 s at
94 C, 45 s at 53 C, and 1.5 min at 72 C. The ampliﬁed DNA
segment was puriﬁed and subjected to nucleotide sequencing.
According to the sequencing result, a pair of primers (sense: 5 0-
TTTGGATCCATGCAATACGCGCTATTA-3 0, and antisense: 5 0-
GGGGAAGCTTTCACACGTATTCTAA-3 0) was synthesized to
amplify the fabD gene from H. pylori strain SS1. The following pro-
tocol was conducted for ampliﬁcation: 30 s at 94 C, 30 s at 50 C,
and 1 min at 72 C, 30 cycles. The PCR products were digested with
restriction endonuclease BamHI and HindIII (Fermentas), and
ligated into a prokaryotic expression vector pQE30 (Qiagen) to pro-
duce the recombinant plasmid pQE30-HpfabD that contains an
N-terminal six-histidine tag for puriﬁcation purpose. After the re-
combinant clone pQE30-HpfabD was sequenced, the nucleotide se-
quence of fabD gene from H. pylori strain SS1 was submitted to
GenBank database under the Accession No. AY738332.
2.3. Expression and puriﬁcation of HpMCAT
pQE30-HpfabD was transformed into E. coli strain M15 growing in
LB media supplemented with 100 lg/ml of ampicillin and 50 lg/ml of
kanamycin at 37 C. When OD600 reached 0.8, the culture was induced
by 0.4 mM isopropyl-b-D-thiogalasctopyranoside and incubated at
37 C for an additional 6 h. The cells were harvested by centrifugation
at 6000 · g for 15 min at 4 C and suspended in buﬀer A (20 mM Tris–
HCl, pH 8.0, 500 mM NaCl, and 5 mM imidazole). After sonication
treatment on ice, the mixture yielded a clear supernatant by centrifuga-
tion at 16000 · g for 45 min at 4 C, which was loaded onto a column
with Ni-NTA resin (Qiagen) pre-equilibrated in buﬀer A. The columnFig. 1. Chemical structure of corytuberine, the identiﬁed inhibitor
against HpMCAT.was washed with buﬀer B (20 mM Tris–HCl, pH 8.0, 500 mM NaCl,
and 40 mM imidazole) for several times and eluted with buﬀer C
(20 mM Tris–HCl, pH 8.0, 500 mM NaCl, and 500 mM imidazole).
The proper concentration ofHpMCAT was obtained by ultra ﬁltration
using Amicon centrifugal device and determined by measuring the
absorbance at 280 nm with the extinction coeﬃcient of 19785 L/mol/
cm.
2.4. Circular dichroism (CD) technique based unfolding analysis
All the CD spectral investigations for HpMCAT were carried out
using a JASCO J-810 spectropolarimeter under constant nitrogen ﬂow.
The HpMCAT concentration was 0.3 mg/ml in 50 mM, pH 6.8, phos-
phate buﬀer for far-UV (190–250 nm) assay using 1 mm quartz cell.
To determine the temperature-induced unfolding of HpMCAT, the
change of ellipticity at 220 nm was recorded at a scan speed of
0.2 C/min from 20 to 90 C. Since the buﬀer solution showed no
changes with the increase of temperature, the potential buﬀer-caused
eﬀect could be neglected during data analysis.
During the guanidinium hydrochloride (GndHCl)-induced unfold-
ing experiment, the spectra were obtained with 2-h incubation at room
temperature including the supplement of corresponding concentration
of GndHCl. Experimental data were corrected by subtracting the
blank obtained under the same conditions in the absence of protein
sample.
The standard free energy change of GndHCl-induced unfolding pro-
cess (DG) for HpMCAT was obtained in terms of the typical two state
transition mechanism. In this unfolding reaction, the equilibrium con-
stant (Ku) could be expressed as follows:
Ku ¼ ð1 F appÞ=F app; F app ¼ ðh hUÞ=ðhN  hUÞ; ð1Þ
where h is the observed ellipticity value in 220 nm of HpMCAT at a
given GndHCl concentration, hU and hN are the ellipticity values when
HpMCAT is completely unfolded and in native state, respectively. The
calculation of the standard free energy of GndHCl-induced unfolding
(DG) is obtained according to the following equation:
DG ¼ RT lnðKuÞ; ð2Þ
where R is the gas constant, T is the absolute temperature. DG is then
ﬁtted to the linear regression by the concentration of GndHCl (C)
using the following equation [19]:
DG ¼ mC þ DGH2O; ð3Þ
where the slope (m) is the cooperative index, which reﬂects the ability
of the denaturant to unfold a protein. DGH2O could be calculated by
linear extrapolation, which represents the structural stability of
HpMCAT in buﬀer. At the midpoint concentration of GndHCl
(Cm), DG is zero, Cm could be thus calculated according to Eq. (3).2.5. Enzyme activity assay
The enzymatic activity of HpMCAT was measured by using the a-
ketoglutarate dehydrogenase (KDH)-coupled assay system [20]. In this
system, the coenzyme A (CoASH) generated by HpMCAT is the sub-
strate for the KDH-dependent reaction, which is accompanied by the
reduction of NAD+ to NADH. The rate of NAD+ is detected as a
change in ﬂuorescence using a 96-well plate system (Tecan GENios
reader) with an excitation wavelength at 340 nm and the emission
wavelength at 465 nm. The assay solution contained 50 mM phosphate
buﬀer (pH 6.8), 1 mM EDTA, 1 mM DTT, 2 mM a-ketoglutaric acid,
0.25 mM NAD+, 0.2 mM TPP, 1 lg HpMCAT, 10 lM acyl carrier
protein (ACP), 5 mU/100 ll KDH, and 25 lM malonyl-CoA. The
reaction was formed in the following order with 50 ll HpMCAT solu-
tion, 25 ll ACP/KDH mix, and then 25 ll malonyl-CoA to initiate the
reaction. The change of NADH ﬂuorescence was recorded for 30 min
at 30 C.
The concentrations of malonyl-CoA were individually varied as re-
quired to obtain the Km value for HpMCAT toward malonyl-CoA.
The inﬂuence of temperature on the enzymatic activity was determined
from 20 to 50 C.
For the enzyme inhibition studies, the test compound dissolved in
1% DMSO was pre-incubated with HpMCAT at 30 C for 1 h before
the reaction was started. In considering that the inhibitor might inter-
fere with the activity of KDH, the counter-screen was performed
against KDH to identify its eﬀect on the KDH activity [20].
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3.1. fabD gene sequence analysis
In the current work, the fabD gene from H. pylori strain SS1
(HpfabD) was successfully cloned based on the available gen-
ome sequences of H. pylori strains 26695 and J99, and the re-
combinant expression plasmid pQE30-HpfabD was generated
by inserting the ampliﬁed fabD fragment into the vector
pQE30. The HpfabD gene was a 930 bp fragment including
the stop codon.
Fig. 2 showed the amino acid sequence alignment of
HpMCAT with other MCATs from several other model
organisms by Clustal W (www.ebi.ac.uk/clustalw). It was
found that HpMCAT shared 32% identity and 53% similar-
ity with MCAT of E. coli (EcMCAT) in amino acid se-
quence. In addition, two highly conserved motifs (GHSXH,
PGQGXQ) and other conserved residues were observed.
According to the previous reports involving the crystallo-
graphic and catalytic mechanism analyses for MCAT,
MCAT performs the transfer of malonyl to holo-ACP
including two reactions [4,7,10]. Firstly, the MCAT binds
the malonyl-CoA substrate to form a stable tetrahedral mal-
onyl-MCAT intermediate, the holo-ACP could then dock on
the surface of the intermediate by hydrophobic interaction
[10]. Thus, MCAT enzyme was generally considered to con-
tain at least two active sites, the malonyl-CoA binding site
and the holo-ACP binding site. It is suggested that the two
highly conserved motifs and residues might be related to
the active sites formation [2,10,13].Fig. 2. Multiple alignment of MCAT sequences from diﬀerent species.
Streptomyces coelicolor (S. coelicolor), Helicobacter pylori (H. pylori). The st
substitutions are represented as ‘‘:’’, and ‘‘.’’ means the semi-conserved
www.ebi.ac.uk/clustal/index.html website.3.2. Puriﬁcation and characterization of HpMCAT
HpMCAT could be successfully expressed as a fusion pro-
tein with an N-terminal 6· His tag. It could be puriﬁed by a
one-step puriﬁcation protocol judged from SDS–PAGE
(Fig. 3A), and Electron-spray ionization mass spectrometry
yielded a molecular mass about 35755 Da (Supplementary
material), in good agreement with the calculated molecular
mass according to the amino acids compositions.
The far-UV CD spectrum of native HpMCAT in, pH 6.8,
50 mM phosphate buﬀer at 25 C revealed two negative peaks
at 209 and 220 nm, implying that this protein contains a signif-
icant amount of a-helix as shown in Fig. 3B [21]. According to
the JASCO secondary structure estimation software, in the na-
tive state of HpMCAT, its a-helix is about 64.2%, which is
higher than that obtained from EcMCAT based on its crystal
structure (49.5%, a-helix) [13].3.3. Enzymatic kinetics analysis
It is known that HpMCAT catalyzes the transfer of a
malonyl moiety from malonyl-CoA to the free thiol of
phosphopantetheine arm of ACP using the ping-pong mech-
anism [10,20], which could be depicted in the reactions as
follows:
Malonyl-CoA+holo-ACP$malonyl-ACP+CoASH ð4Þ
CoASH+NADþ + a-ketoglutarate
! succinyl-CoA+NADH+CO2
ð5ÞEscherichia coli (E. coli), Pseudomonas aeruginosa (P. aeruginosa),
rictly conserved residues are marked with asterisk ‘‘*’’. The conserved
substitutions. Alignment was performed using Clustal W at http://
Fig. 4. Kinetic analysis of HpMCAT toward malonyl-CoA using the
ﬂuorometric coupled enzyme assay. The assay was performed as
described in Section 2. The Km for HpMCAT toward malonyl-CoA
value was obtained upon the data analysis by double reciprocal plot.
Fig. 5. Eﬀect of temperature on the HpMCAT enzymatic activity.
Fig. 3. Characterization of the puriﬁed HpMCAT. (A) SDS–PAGE in
5%, pH 6.8, stacking gel and 10%, pH 8.8, separating gel. Lane 1,
molecular mass marker; lane 2, HpMCAT. (B) Far-UV CD spectra of
HpMCAT.
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change in ﬂuorescence. The enzymatic results thus showed that
HpMCAT was active with Km at 21.01 ± 2.3 lM toward the
malonyl-CoA as indicated in Fig. 4, similar to that of EcM-
CAT [20], and smaller than that of ScMCAT [22]. In addition,
theHpMCAT enzyme showed the highest enzymatic activity at
30 C. When the temperature was increased to 50 C, the en-
zyme could only possess about 20% activity as shown in Fig. 5.
3.4. Enzyme unfolding analyses
To determine the inﬂuence of temperature on the stability of
HpMCAT, the thermal-induced unfolding experiment was car-
ried out using CD technique. As shown in Fig. 6A, HpMCAT
began to lose its secondary structure at 50 C, and its secondary
structure was totally destroyed when the temperature was raised
to 70 C. However, it is noticed that the enzymatic activity of
HpMCAT was mostly vanished even when the temperature
was raised to 45 Cas indicated in Fig. 5. This result implied that
the secondary structure ofHpMCAT seems to be more thermo-
stable in comparison with its three-dimensional structure.In order to further gain insights into the thermal-induced
unfolding process, the thermodynamic parameters for
HpMCAT were quantitatively analyzed [23,24]. As shown in
Fig. 6A, the change of ellipticity at 220 nm with the increase
of temperature demonstrates that the thermal-induced unfold-
ing process of HpMCAT is cooperative and follows a typical
two-state pattern. The apparent activation energy (Ea) of the
transition ofHpMCAT could be obtained according to the fol-
lowing equation [24]:
lnðlnð1=F appÞÞ ¼ Ea=Rð1=Tm  1=T Þ; ð6Þ
where Fapp is deﬁned as the fraction of native protein at the cor-
responding temperature. Fapp is equal to the (h  hU)/
(hN  hU), h is the observed ellipticity value in 220 nm of
HpMCAT at a given temperature, hU and hN are the ellipticity
values when theHpMCAT is completely unfolded and in native
state, respectively. Tm is the temperature at which the maxi-
mum of the heat capacity curve happened. The plot of
Fig. 7. Kinetic analysis of the inhibitory activity for corytuberine
against HpMCAT. The reaction was performed under the conditions
as described in Section 2 in the presence of diﬀerent concentrations of
corytuberine (0, 30, 60, 90 lM) at a range of malonyl-CoA concen-
trations. The data were analyzed by double reciprocal plot. (Inset:
Dose–response curves of enzyme inhibition.)
Table 1
Comparison of Km and Vm of HpMCAT toward malonyl-CoA at
diﬀerent inhibitor (corytuberine) concentrations
Inhibitor concentration (lM) 0 30 60 90
Km (lM) 21.01 16.38 14.65 12.76
Vm (RFU/min) 114.9 68.5 28.41 22.03
Fig. 6. Unfolding analysis of HpMCAT determined by far-UV CD
spectra. (A) Thermal-induced unfolding. The ellipticity value at 220
nm of HpMCAT (0.3 mg/ml) was recorded from 20 to 90 C with the
scan rate of 2 C/min. The inset shows the relationship between the
ln(ln(1/Fapp)) and 1/T (Eq. (6)). (B) GndHCl-induced unfolding. The
ellipticity value at 220 nm of HpMCAT (0.3 mg/ml) was monitored at
the function of GndHCl at 25 C. The inset reveals the linear
relationship between the free energy (DG) and the GndHCl concen-
trations.
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tion (Fig. 6A, inset). According to Eq. (6), at pH 6.8 the appar-
ent activation energy (Ea) of HpMCAT and Tm were estimated
to be 160.1 ± 6.6 (kJ/mol) and 65.5 ± 2.5 C, respectively.
It is known that GndHCl is the most commonly used ion-
denaturant in the evaluation of protein stability [24]. To inves-
tigate the eﬀect of detergent on the stability of HpMCAT,
GndHCl-induced unfolding assay for HpMCAT was per-
formed using CD technique. As shown in Fig. 6B, a single
transition was observed with increasing GndHCl concentra-
tions from 0.7 to 4 M. On the basis of the experimental data,
the GndHCl-induced unfolding could be also described in a
two-state pathway, similar to the thermal-induced unfolding
nature as indicated in Fig. 6. According to Eqs. (2) and (3),
the Cm value (1.3 ± 0.2 M GndHCl), m value (3.58 ± 0.5 kJ/
mol) and DGH2O of unfolding (4.67 ± 0.7 kJ/mol) could be
obtained.3.5. Corytuberine is an uncompetitive inhibitor of HpMCAT
It is known that MCAT could catalyze the formation of mal-
onyl-ACP, which is a key substrate for the biosynthesis of fatty
acid in bacteria (FAS II). Accordingly, MCAT has been
developed as a promising drug target for antibacterial agent
discovery. In the current work, we have constructed the
high-throughput screening (HTS) assay for the discovery of
the potent small molecular inhibitors against HpMCAT based
on our natural products library. Up to now, several inhibitors
against some other enzymes involved in FAS II process have
been investigated. For example, triclosan and diazaborine
showed inhibitory activity against the enoyl-ACP reductase
(FabI) [25–27]. However, no inhibitor has been reported
against MCAT enzyme [1,2,28]. In the current work, we ﬁrstly
discovered a small natural compound, corytuberine (Fig. 1),
which demonstrated evidently enzymatic inhibitory activity
against HpMCAT and no eﬀects on KDH (data not shown)
during the enzymatic inhibition assay. This result thereby indi-
cates that corytuberine is a potent inhibitor against HpMCAT.
The IC50 value for this inhibition was evaluated as
33.1 ± 3.29 lM (Fig. 7, inset) by ﬁtting the inhibition data to
a dose-dependent curve using a logistic derivative equation.
To further elucidate the inhibition mode of corytuberine
against HpMCAT, the enzymatic kinetic studies were carried
out according to the published methods [20,29]. The results
showed that with malonyl-CoA as the variable substrate,
corytuberine gave the uncompetitive inhibition pattern with
respect to malonyl-CoA according to the double reciprocal
plot as shown in Fig. 7 and Table 1.
In conclusion, we described the clone and expression of a no-
vel MCAT fromH. pylori (HpMCAT), the sequence alignment
702 W. Liu et al. / FEBS Letters 580 (2006) 697–702demonstrated that MCAT is a conserved enzyme among diﬀer-
ent species. The biochemical characterization and stability
investigation of HpMCAT were carried out by CD spectral as-
say, which provided some useful insights into the understand-
ing of the HpMCAT enzyme. Furthermore, a small molecular
natural product, corytuberine, was discovered as a potent
inhibitor against HpMCAT. To our knowledge, this is the ﬁrst
MCAT inhibitor to date. Further enzymatic dynamic assay
indicated that corytuberine inhibits HpMCAT in an uncom-
petitive manner. This current work is hoped to supply useful
information for better understanding the MCAT features of
H. pylori strain and further providing possible hints in the dis-
covery of the antibacterial compounds using HpMCAT as tar-
get. The inhibitor, corytuberine, might be used as a potential
lead compound in the discovery of antibacterial agents.
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